Literature DB >> 31129085

The loss of β adrenergic receptor mediated release potentiation in a mouse model of fragile X syndrome.

Nuria García-Font1, Ricardo Martín1, Magdalena Torres2, María Jesus Oset-Gasque3, José Sánchez-Prieto4.   

Abstract

In fragile X syndrome, the absence of Fragile X Mental Retardation Protein (FMRP) is known to alter postsynaptic function, although alterations in presynaptic function also occur. We found that the potentiation of glutamate release induced by the β adrenergic receptor (βAR) agonist isoproterenol is absent in cerebrocortical nerve terminals (synaptosomes) from mice lacking FMRP (Fmr1 KO), despite the normal cAMP generation. The glutamate release induced by moderate stimulation of synaptosomes with 5 mM KCl was not potentiated in Fmr1 KO synaptosomes by isoproterenol, nor by stimulating the receptor associated signaling pathway with the adenylyl cyclase activator forskolin or with the Epac activator 8-pCPT. Hence, the impairment in the pathway potentiating release is distal to βARs. Electron microscopy shows that Fmr1 KO cortical synapses have more docked vesicles than WT synapses, consequently occluding the isoproterenol response through which more SVs approach the active zone (AZ) of the plasma membrane. Weak stimulation of synaptosomes with the Ca2+ ionophore ionomycin recovered the release potentiation driven by forskolin and 8-pCPT but not with isoproterenol, revealing an impairment in the efficiency of receptor generated cAMP to activate the release potentiation pathway. Indeed, inhibiting cyclic nucleotide phosphodiesterase PDE2A with BAY 60-7550 reestablished isoproterenol mediated potentiation in Fmr1 KO synaptosomes. Thus, the lack of β-AR mediated potentiation of glutamate release appears to be the consequence of an impaired capability of the receptor to mobilize SVs to the AZ and because of a decreased efficiency of cAMP to activate the signaling pathway that enhances neurotransmitter release.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cerebrocortical nerve terminals; Docked synaptic vesicles; Fmr1 KO mice; Fragile X syndrome; Glutamate release; Phosphodiesterase 2; Ready releasable pool; cAMP; β adrenergic receptors

Mesh:

Substances:

Year:  2019        PMID: 31129085     DOI: 10.1016/j.nbd.2019.104482

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  4 in total

Review 1.  Imaging Synaptic Density: The Next Holy Grail of Neuroscience?

Authors:  Maria Elisa Serrano; Eugene Kim; Marija M Petrinovic; Federico Turkheimer; Diana Cash
Journal:  Front Neurosci       Date:  2022-03-25       Impact factor: 4.677

2.  Chemical Stimulation of Rodent and Human Cortical Synaptosomes: Implications in Neurodegeneration.

Authors:  Faraz Ahmad; Yu Jing; Albert Lladó; Ping Liu
Journal:  Cells       Date:  2021-05-12       Impact factor: 6.600

Review 3.  Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders.

Authors:  Sébastien Delhaye; Barbara Bardoni
Journal:  Mol Psychiatry       Date:  2021-01-07       Impact factor: 15.992

4.  Phosphodiesterase 2A inhibition corrects the aberrant behavioral traits observed in genetic and environmental preclinical models of Autism Spectrum Disorder.

Authors:  Barbara Bardoni; Viviana Trezza; Sara Schiavi; Emilia Carbone; Francesca Melancia; Alessandra di Masi; Marielle Jarjat; Fréderic Brau; Silvia Cardarelli; Mauro Giorgi
Journal:  Transl Psychiatry       Date:  2022-03-25       Impact factor: 6.222

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.